君实生物(688180)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

688180 君实生物

已收盘 11-19 15:00:00

{"stockData":{"symbol":"688180","market":"SH","secType":"STK","nameCN":"君实生物","latestPrice":29.94,"timestamp":1731999600000,"preClose":29.68,"halted":0,"volume":5878011,"delay":0,"floatShares":765000000,"shares":986000000,"eps":-1.8296,"marketStatus":"已收盘","marketStatusCode":5,"change":0.26,"latestTime":"11-19 15:00:00","open":29.97,"high":30.14,"low":29.33,"amount":175000000,"amplitude":0.0273,"askPrice":29.94,"askSize":18,"bidPrice":29.93,"bidSize":716,"shortable":0,"etf":0,"ttmEps":-1.8296,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1732066200000},"adr":0,"adjPreClose":29.68,"symbolType":"stock_kcb","openAndCloseTimeList":[[1731979800000,1731987000000],[1731992400000,1731999600000]],"highLimit":32.65,"lowLimit":26.71,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":985689871,"pbRate":4.78,"roa":"--","roe":"--","epsLYR":-2.32,"committee":0.757216,"marketValue":29512000000,"floatMarketCap":22891000000,"peRate":-16.364233,"changeRate":0.0088,"turnoverRate":0.0077,"status":0,"afterMarket":{"amount":0,"volume":0,"close":29.94,"buyVolume":0,"sellVolume":0,"time":1732001639464,"indexStatus":"已收盘 11-19 15:30:00","preClose":29.68}},"requestUrl":"/m/hq/s/688180/wiki","defaultTab":"wiki","newsList":[{"id":"2484966626","title":"《股市简讯》中国君实生物A/H股齐升，英国批准特瑞普利单抗上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2484966626","media":"路透中文","labels":["Company Corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484966626?lang=zh_cn&edition=full","pubTime":"2024-11-18 11:56","pubTimestamp":1731902217,"startTime":"0","endTime":"0","summary":"《股市简讯》中国君实生物A/H股齐升，英国批准特瑞普利单抗上市* 中国生物科技公司君实生物688180.SS周一早盘一度升3.8%，早市收高2.7%；其H股1877.HK涨幅扩大至5.5%。* 该公司此前公告称，特瑞普利单抗获得英国药品和保健品管理局批准上市，成为英国首个且唯一用于鼻咽癌治疗的药物。nL4T3MO03K* 君实生物今年迄今大跌33.5%，同期恒生指数.HSI大幅上扬15.3%。* 恒生香港上市生物科技指数.HSHKBIO盘中一度跌1.8%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241118:nL4T3MP094:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Company Corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","BK1515","01877","688180","BK1161","BK0239"],"gpt_icon":0},{"id":"2484698316","title":"君实生物AH股齐涨，特瑞普利单抗获英国当局批准上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2484698316","media":"格隆汇","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484698316?lang=zh_cn&edition=full","pubTime":"2024-11-18 10:54","pubTimestamp":1731898453,"startTime":"0","endTime":"0","summary":"君实生物港股一度涨5.5%报13.04港元，A股一度涨3.84%报30.55元。消息面上，君实生物昨晚表示，其全资子公司TopAlliance Biosciences Inc.产品特瑞普利单抗获得英国药品和保健品管理局(MHRA)核准签发的上市许可，批准用于治疗两项适应症。特瑞普利单抗联合顺铂和吉西他滨用于复发、不能手术或放疗的，或转移性鼻咽癌成人患者的一线治疗，以及特瑞普利单抗联合顺铂和紫杉醇用于不可切除的晚期/复发或转移性食管鳞癌成人患者的一线治疗。特瑞普利单抗成为英国首个且唯一用于鼻咽治疗的药物。\n\n\r\n            责任编辑：栎树","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/11/18105445388225.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["688180","01877","BK1515","BK0239","BK1583","BK1161"],"gpt_icon":0},{"id":"2484466618","title":"金十数据整理：每日港股市场要闻速递（11月18日 周一）","url":"https://stock-news.laohu8.com/highlight/detail?id=2484466618","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484466618?lang=zh_cn&edition=full","pubTime":"2024-11-18 09:03","pubTimestamp":1731891836,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["LU1568876335.HKD","03347","IE00BZ08YT58.USD","LU0791590937.USD","BK1502","LU0345775950.USD","LU0449509016.USD","LU1831875114.USD","SG9999002828.SGD","89618","LU0594300179.USD","SG9999001051.SGD","89988","02429","LU0181495838.USD","BK0266","LU0797268264.HKD","06185","601898","LU1568876251.USD","LU0708995153.HKD","BK0028","LU0737861772.HKD","BK1575","LU1770036033.HKD","LU1481107354.HKD","09988","HSTECH","BK0188","JD","03398","BK1608","01877","HSCEI","YANG","HBBD.SI","00984","BABA","LU0231483743.USD","LU1152091168.USD","LU1794554557.SGD","688180","159646","BK4554","07226","LU0531971595.HKD","01898","09618","LU0214875030.USD","LU1008478684.HKD"],"gpt_icon":0},{"id":"2484021955","title":"君实生物(688180.SH)：特瑞普利单抗获英国上市许可 系英国首个且唯一用于鼻咽癌治疗药物","url":"https://stock-news.laohu8.com/highlight/detail?id=2484021955","media":"智通财经","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484021955?lang=zh_cn&edition=full","pubTime":"2024-11-17 15:42","pubTimestamp":1731829342,"startTime":"0","endTime":"0","summary":"智通财经APP讯，君实生物(688180.SH)发布公告，公司全资子公司TopAlliance Biosciences Inc.产品特瑞普利单抗(英国商品名：LOQTORZI®)获得英国药品和保健品管理局(简称“MHRA”)核准签发的上市许可，批准用于治疗两项适应症：特瑞普利单抗联合顺铂和吉西他滨用于复发、不能手术或放疗的，或转移性鼻咽癌成人患者的一线治疗，以及特瑞普利单抗联合顺铂和紫杉醇用于不可切除的晚期/复发或转移性食管鳞癌成人患者的一线治疗。特瑞普利单抗成为英国首个且唯一用于鼻咽癌治疗的药物，也是英国唯一用于不限PD-L1表达的晚期或转移性食管鳞癌一线治疗药物。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1211937.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","BK0239","688180","01877","BK1161","BK1515"],"gpt_icon":0},{"id":"2483938115","title":"君实生物：用于鼻咽癌治疗的特瑞普利单抗获得英国MHRA批准上市。","url":"https://stock-news.laohu8.com/highlight/detail?id=2483938115","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483938115?lang=zh_cn&edition=full","pubTime":"2024-11-16 16:27","pubTimestamp":1731745666,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["688180","BK0239","01877","BK1515","BK1583","BK1161"],"gpt_icon":0},{"id":"2483374468","title":"君实生物(01877)： 特瑞普利单抗获得英国药品和保健品管理局批准上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2483374468","media":"智通财经","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483374468?lang=zh_cn&edition=full","pubTime":"2024-11-15 22:28","pubTimestamp":1731680899,"startTime":"0","endTime":"0","summary":"智通财经APP讯，君实生物(01877)发布公告，公司全资附属公司TopAlliance Biosciences Inc.产品特瑞普利单抗(英国商品名：LOQTORZI®)获得英国药品和保健品管理局核准签发的上市许可，批准用于治疗两项适应症：特瑞普利单抗联合顺铂和吉西他滨用于复发、不能手术或放疗的，或转移性鼻咽癌成人患者的一线治疗，以及特瑞普利单抗联合顺铂和紫杉醇用于不可切除的晚期╱ 复发或转移性食管鳞癌成人患者的一线治疗。特瑞普利单抗成为英国首个且唯一用于鼻咽癌治疗的药物，也是英国唯一用于不限PD-L1表达的晚期或转移性食管鳞癌一线治疗药物。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1211872.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","BK1161","BK0239","01877","688180","BK1515"],"gpt_icon":0},{"id":"2483193313","title":"君实生物盘中异动 快速下挫5.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2483193313","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483193313?lang=zh_cn&edition=full","pubTime":"2024-11-15 14:48","pubTimestamp":1731653326,"startTime":"0","endTime":"0","summary":"2024年11月15日下午盘14时48分，君实生物股票出现异动，股价快速下挫5.01%。截至发稿，该股报12.140港元/股，成交量348.34万股，换手率1.59%，振幅5.16%。君实生物股票所在的生物技术行业中，整体跌幅为0.43%。其相关个股中，永泰生物-B、北海康成-B、迈博药业-B涨幅较大，振幅较大的相关个股有北海康成-B、荃信生物-B、晶泰科技，振幅分别为25.64%、24.62%、22.15%。药品批发,药品委托生产。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241115144846971a6c04&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241115144846971a6c04&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01877","BK1515","BK1583","BK1161","688180"],"gpt_icon":0},{"id":"2483319320","title":"君实生物(01877)下跌5.01%，报12.14元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2483319320","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483319320?lang=zh_cn&edition=full","pubTime":"2024-11-15 14:48","pubTimestamp":1731653325,"startTime":"0","endTime":"0","summary":"11月15日，君实生物(01877)盘中下跌5.01%，截至14:48，报12.14元/股，成交4296.41万元。上海君实生物医药科技股份有限公司主要业务是发现、开发和商业化创新疗法，特别是在肿瘤免疫疗法、自身免疫系统疾病、慢性代谢类疾病、神经系统疾病、感染类疾病等治疗方面。公司拥有卓越的创新药物发现能力、先进的生物技术研发、全产业链大规模生产技术和极具市场潜力的在研药品组合。截至2024年三季报，君实生物营业总收入12.71亿元、净利润-9.27亿元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/11/15144845331763.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["01877","688180","BK1161","BK1583","BK1515","BK0239"],"gpt_icon":0},{"id":"2483693045","title":"【AH互动】君实生物跌近8% 近日遭股东合计减持739.26万股A股","url":"https://stock-news.laohu8.com/highlight/detail?id=2483693045","media":"金吾资讯","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483693045?lang=zh_cn&edition=full","pubTime":"2024-11-13 13:19","pubTimestamp":1731475159,"startTime":"0","endTime":"0","summary":"金吾财讯 | 君实生物(01877)近日遭股东减持，早盘股价受压走低，午后维持低位，截至发稿，报13.3港元，跌7.89%，成交额2393.27万港元。对应A股君实生物(688180)同步下滑，暂报31.38元人民币，跌4.33%，成交额2.5亿元人民币。据公告，今年10月23日至11月12日期间，持股5%以上股东上海檀英、上海檀正，通过集中竞价方式合计减持公司739.26万股A股，减持比例占公司总股本0.75%。截至11月12日，本次减持计划已实施完毕。据披露，本次股份减持计划实施前，上海檀英、上海檀正合计持有君实生物7,885.2万股A股，占公司总股本8%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241113131937abbc0f60&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241113131937abbc0f60&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","01877","BK1515","688180","BK1583"],"gpt_icon":0},{"id":"2483801169","title":"港股异动 | AH股齐跌 君实生物(01877)盘中跌逾7% 近月遭多股东减持逾739万股A股","url":"https://stock-news.laohu8.com/highlight/detail?id=2483801169","media":"智通财经","labels":["Shareholding Changes","movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483801169?lang=zh_cn&edition=full","pubTime":"2024-11-13 11:16","pubTimestamp":1731467786,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，君实生物(01877)AH股齐跌，H股盘中跌逾7%，截至发稿，跌7.34%，报13.38港元，成交额1926.7万港元。消息面上，君实生物公布，今年10月23日至11月12日期间，持股5%以上股东上海檀英、上海檀正，通过集中竞价方式合计减持公司739.26万股A股，减持比例占公司总股本0.75%。截至昨日(12日)，本次减持计划已实施完毕。据披露，本次股份减持计划实施前，上海檀英、上海檀正合计持有君实生物7,885.2万股A股，占公司总股本8%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1210236.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"Shareholding Changes,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01877","399300","BK1515","BK1583","BK0239","159982","BK1161","688180"],"gpt_icon":0},{"id":"2483013012","title":"君实生物(01877)下跌5.26%，报13.68元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2483013012","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483013012?lang=zh_cn&edition=full","pubTime":"2024-11-13 10:31","pubTimestamp":1731465078,"startTime":"0","endTime":"0","summary":"11月13日，君实生物(01877)盘中下跌5.26%，截至10:31，报13.68元/股，成交743.63万元。上海君实生物医药科技股份有限公司主要业务是发现、开发和商业化创新疗法，特别是在肿瘤免疫疗法、自身免疫系统疾病、慢性代谢类疾病、神经系统疾病、感染类疾病等治疗方面。公司拥有卓越的创新药物发现能力、先进的生物技术研发、全产业链大规模生产技术和极具市场潜力的在研药品组合。截至2024年三季报，君实生物营业总收入12.71亿元、净利润-9.27亿元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/11/13103145232059.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0239","BK1161","01877","BK1515","688180","BK1583"],"gpt_icon":0},{"id":"2483901371","title":"君实生物盘中异动 股价大跌5.26%报13.680港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2483901371","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483901371?lang=zh_cn&edition=full","pubTime":"2024-11-13 10:31","pubTimestamp":1731465076,"startTime":"0","endTime":"0","summary":"2024年11月13日早盘10时31分，君实生物股票出现波动，股价大幅下挫5.26%。截至发稿，该股报13.680港元/股，成交量53万股，换手率0.24%，振幅6.51%。资金方面，该股资金流入234.313万港元，流出342.92万港元。君实生物股票所在的生物技术行业中，整体跌幅为2.05%。其相关个股中，贝康医疗-B、腾盛博药-B、华康生物医学涨幅较大，振幅较大的相关个股有宜明昂科-B、腾盛博药-B、乐普生物-B，振幅分别为19.76%、12.96%、11.83%。药品批发,药品委托生产。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241113103116abbba99e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241113103116abbba99e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688180","BK0239","01877"],"gpt_icon":0},{"id":"2483092898","title":"南向资金11月12日净卖出君实生物27.96万股 连续5日减持","url":"https://stock-news.laohu8.com/highlight/detail?id=2483092898","media":"市场透视","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483092898?lang=zh_cn&edition=full","pubTime":"2024-11-13 09:30","pubTimestamp":1731461414,"startTime":"0","endTime":"0","summary":"11月12日，南向资金减持君实生物27.96万股连续5日减持。截止当日收盘，港股通共持有君实生物8848.14万股，占流通股40.34%。君实生物近5个交易日上涨6.18%，港股通累计减持75.00万股；近20个交易日上涨6.49%，港股通累计减持220.54万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241113093135a231f0dd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241113093135a231f0dd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01877","688180","BK0239"],"gpt_icon":0},{"id":"2483969250","title":"君实生物(01877.HK)遭股东近月减持逾739万股A股 占股本0.75%","url":"https://stock-news.laohu8.com/highlight/detail?id=2483969250","media":"阿斯达克财经","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483969250?lang=zh_cn&edition=full","pubTime":"2024-11-13 08:24","pubTimestamp":1731457440,"startTime":"0","endTime":"0","summary":"君实生物(01877.HK) (688180.SH) 公布，今年10月23日至11月12日期间，持股5%以上股东上海檀英、上海檀正，通过集中竞价方式合计减持公司739.26万股A股，减持比例占公司总股本0.75%。截至昨日(12日)，本次减持计划已实施完毕。据披露，本次股份减持计划实施前，上海檀英、上海檀正合计持有君实生物7,885.2万股A股，占公司总股本8%。(js/w)(港股报价延迟最少十五分钟。沽空资料截至 2024-11-12 16:25。) (A股报价延迟最少十五分钟。)AASTOCKS新闻","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20200529130906781_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20200529130906781_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1396159/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK0239","688180","159982","BK1515","BK1161","01877","BK1583","399300"],"gpt_icon":0},{"id":"2482870905","title":"君实生物(01877)股东上海檀英、上海檀正合计减持约739.27万股A股股份 减持计划已实施完毕","url":"https://stock-news.laohu8.com/highlight/detail?id=2482870905","media":"智通财经","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482870905?lang=zh_cn&edition=full","pubTime":"2024-11-12 21:04","pubTimestamp":1731416642,"startTime":"0","endTime":"0","summary":"智通财经APP讯，君实生物(01877)公布，公司于 2024 年 11 月 12 日收到上海檀英及上海檀正关于减持计划完成暨减持股份结果的通知，2024 年 10 月 23 日至 2024 年 11 月 12 日期间，上海檀英、上海檀正通过集中竞价方式合计减持公司 A 股股份 7,392,674 股，减持比例占公司总股本的 0.75%。截至 2024 年 11 月 12 日，本次减持计划已实施完毕。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1210067.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159982","399300","01877","688180","BK1583","BK1161","BK0239","BK1515"],"gpt_icon":0},{"id":"2482870385","title":"11月12日君实生物发布公告，其股东减持520.89万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2482870385","media":"证券之星","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482870385?lang=zh_cn&edition=full","pubTime":"2024-11-12 20:01","pubTimestamp":1731412865,"startTime":"0","endTime":"0","summary":"证券之星消息，11月12日君实生物发布公告《君实生物:君实生物关于持股5%以上股东减持计划完成暨减持股份结果的公告》，其股东上海檀英投资合伙企业(有限合伙)、上海檀正投资合伙企业(有限合伙)于2024年10月30日至2024年11月12日间合计减持520.89万股，占公司目前总股本的0.5285%，变动期间该股股价上涨6.98%，截止11月12日收盘报32.8元。股东增减持详情见下表：根据君实生物2024年中报公布的十大股东详情如下：以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024111200033614.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688180","BK1161","BK1583","BK1515","BK0239","01877"],"gpt_icon":0},{"id":"2482772927","title":"君实生物(688180.SH)股东上海檀英及上海檀正合计减持公司0.75%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2482772927","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482772927?lang=zh_cn&edition=full","pubTime":"2024-11-12 19:17","pubTimestamp":1731410264,"startTime":"0","endTime":"0","summary":"智通财经APP讯，君实生物(688180.SH)发布公告，公司于2024年11月12日收到股东上海檀英及上海檀正关于减持计划完成暨减持股份结果的通知，2024年10月23日至2024年11月12日期间，上海檀英、上海檀正通过集中竞价方式合计减持公司A股股份739.27万股，减持比例占公司总股本的0.75%。截至2024年11月12日，本次减持计划已实施完毕。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1209982.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","01877","BK1515","BK1583","688180","BK1161"],"gpt_icon":0},{"id":"2482718962","title":"君实生物盘中异动 早盘股价大涨5.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2482718962","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482718962?lang=zh_cn&edition=full","pubTime":"2024-11-12 09:58","pubTimestamp":1731376728,"startTime":"0","endTime":"0","summary":"2024年11月12日早盘09时58分，君实生物股票出现波动，股价急速拉升5.07%。截至发稿，该股报15.340港元/股，成交量76.86万股，换手率0.35%，振幅5.07%。君实生物股票所在的生物技术行业中，整体涨幅为0.28%。其相关个股中，药明合联、奥星生命科技、瑞科生物-B涨幅较大，振幅较大的相关个股有绿竹生物-B、药明合联、和誉-B，振幅分别为18.42%、12.90%、12.23%。药品批发,药品委托生产。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024111209584898e41eef&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024111209584898e41eef&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01877","BK0239","688180"],"gpt_icon":0},{"id":"2482797075","title":"君实生物-U创1个月新高 生物医药产业蓬勃发展","url":"https://stock-news.laohu8.com/highlight/detail?id=2482797075","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482797075?lang=zh_cn&edition=full","pubTime":"2024-11-12 09:51","pubTimestamp":1731376297,"startTime":"0","endTime":"0","summary":"11月12日，君实生物-U股价大幅上涨，截至09点51分，君实生物-U上涨5.02%，报33.67元/股，创近1个月新高，成交1.77亿元，换手率0.70%。消息解读近年来，为了推动生物医药产业的快速发展，从中央到地方，都出台了一系列的支持政策。在这样的背景之下，虽然我国的生物医药产业起步较晚，但也借着这股东风，呈现出了蓬勃的发展态势。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241112095207abb79d48&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241112095207abb79d48&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","399441","161726","688180"],"gpt_icon":0},{"id":"2482627317","title":"君实生物-U11月11日主力资金流入4136万元 连续5日加仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2482627317","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482627317?lang=zh_cn&edition=full","pubTime":"2024-11-11 15:19","pubTimestamp":1731309592,"startTime":"0","endTime":"0","summary":"11月11日, 君实生物-U股价涨3.82%，报收32.06元，成交金额4.68亿元，换手率1.96%，振幅5.86%，量比1.67。君实生物-U今日主力资金净流入4136万元，连续5日净流入，上一交易日主力净流入1482万元，今日环比增加179.08%。该股近5个交易日上涨6.76%，主力资金累计净流入9683万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流入6513万元，其中净流入天数为13日。该股主力净额占比0.17%，A股市场排名1080/5000，高于行业平均值。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241111152901abb533ec&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241111152901abb533ec&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688180"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2020-07-15","address":"上海市浦东新区中国(上海)自由贸易试验区海趣路36、58号2号楼10层1003室","stockEarnings":[{"period":"1week","weight":-0.0742},{"period":"1month","weight":-0.053},{"period":"3month","weight":0.1285},{"period":"6month","weight":0.0133},{"period":"1year","weight":-0.2988},{"period":"ytd","weight":-0.2905}],"companyName":"上海君实生物医药科技股份有限公司","boardCode":"AI0027","perCapita":"25926股","boardName":"医药制造业","registeredCapital":"98568万元","compareEarnings":[{"period":"1week","weight":-0.0421},{"period":"1month","weight":0.0191},{"period":"3month","weight":0.1595},{"period":"6month","weight":0.0523},{"period":"1year","weight":0.0882},{"period":"ytd","weight":0.1173}],"survey":"　　上海君实生物医药科技股份有限公司主营业务为新药的研发及相关技术的转让和服务,新药的生产和销售,其主要产品与服务项目单克隆抗体药物和其他治疗型蛋白药物的研发与产业化,单克隆抗体药物研发的技术服务与技术转让等。公司提供的技术服务指利用技术平台为客户提供定制服务,包括分子序列的设计及改造、高表达细胞株的构建、小试及中试工艺研究、临床前研究及临床研究样品的制备等。公司为第一家获得NMPA的抗PD-1单克隆抗体上市批准的中国公司。国内首个获批临床的抗PCSK9单抗、全球首个获批临床的抗BTLA单抗和首个在欧美等海外国家及地区获得紧急使用授权（EUA）的国产COVID-19治疗药物埃特司韦单抗。","serverTime":1732008761982,"listedPrice":55.5,"stockholders":"29489人(较上一季度减少0.04%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"君实生物(688180)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供君实生物(688180)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"君实生物,688180,君实生物股票,君实生物股票老虎,君实生物股票老虎国际,君实生物行情,君实生物股票行情,君实生物股价,君实生物股市,君实生物股票价格,君实生物股票交易,君实生物股票购买,君实生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"君实生物(688180)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供君实生物(688180)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}